Pair Name | Parthenolide, Temozolomide | ||
Phytochemical Name | Parthenolide (PubChem CID: 7251185 ) | ||
Anticancer drug Name | Temozolomide (PubChem CID: 5394 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Parthenolide, Temozolomide | |||
Disease Info | [ICD-11: 2F7Z] | Glioma | Investigative | |
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | MGMT | hsa4255 | |
Down-regulation | Activity | NFKB1 | hsa4790 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | T98G | Glioblastoma | Homo sapiens (Human) | CVCL_0556 |
LN-18 | Glioblastoma | Homo sapiens (Human) | CVCL_0392 | |
Result | These findings suggest that NF-κB is a potential target for inducing cell death in gliomas. A targeted combination strategy in which the response to TMZ is synergistically enhanced by the addition of parthenolide which may be useful, especially in chemoresistant gliomas with high MGMT expression. |
No. | Title | Href |
---|---|---|
1 | Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Cancer Lett. 2018 Aug 1;428:77-89. doi: 10.1016/j.canlet.2018.04.033. | Click |